The findings in this verification cohort were consistent with the primary cohort, demonstrating decreased baseline CSF CAMK2A levels in the MS patients compared to the healthy controls (Supplementary Fig. 2B). This evidence concerns the gene CAMK2A and myeloid sarcoma.